April 24, 2023
Platform Lead, Business Intelligence & Development, Singapore Translational Cancer Consortium;
Director, Biomedical Sciences Industry Partnership Office, A*Star
Mr Seck Yee Kwang oversees the industry development for the Health & Biomedical and Food & Consumer sectors at the Agency for Science, Technology & Research (A*STAR). He also leads the Biomedical Sciences Industry Partnership Office, overseeing research and innovation partnerships with strategic industry partners across the public sector research, clinical and university institutions.
Translating the research and innovation efforts across A*STAR and the research ecosystem in Singapore to forge impactful and outcome-driven partnerships with industry is his key focus. Yee Kwang also has a keen interest in understanding the opportunities that future advances in science and technology could bring in disrupting or transforming current industry landscapes and assessing these opportunities for Singapore.
Prior to joining A*STAR, Yee Kwang spent his earlier years at the Singapore Economic Development Board, in various industry and policy roles. This included a stint at the Human Capital Leadership Institute, where he was Head of Partnership Development.
Yee Kwang has a Bachelor’s and Master’s degree in electrical engineering from the University of Illinois at Urbana Champaign, and the University of California, Santa Barbara. His Master’s research focus was on compound semiconductor device modelling. He also obtained a Graduate Certificate of Intellectual Property Law from the IP Academy.
Singapore Translational Cancer Consortium (STCC) has signed its first cross-border partnership with the Australian Victorian Cancer Biobank (VCB) to foster collaborations in translational oncology research. As part of the partnership agreement, STCC and VCB will share its oncology specimen databases, allowing researchers to access a wider array of tissue samples for cancer research. Both organisations will also share tissue banking best practices, and establish outreach programmes to advance clinical research collaborations between the two countries.
SINGAPORE - The development of mRNA-based cancer vaccines in Singapore is being funded by the Ministry of Health (MOH), as part of its support for “competitive cancer research projects” here, said Senior Minister of State for Health Janil Puthucheary.
SINGAPORE – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd).